Oncology and Hematology - Global Oncology Academy

353-368 of 743

Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Brian Slomovitz, MD
- Brian Slomovitz, MD
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
- Brian Slomovitz, MD
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast Cancer
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
MET and Other Emerging Targets in Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®
MET and Other Emerging Targets in Metastatic NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
MinuteCE®
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Applications of Emerging Data in Resectable NSCLC
Applications of Emerging Data in Resectable NSCLC
MinuteCE®
Applications of Emerging Data in Resectable NSCLC
Stephen Liu, MD; Joshua K. Sabari, MD
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits

23/11